Ezetimibe
- Generic Name
- Ezetimibe
- Brand Names
- Ezetrol, Lypqozet, Nexlizet, Roszet, Vytorin, Zetia
- Drug Type
- Small Molecule
- Chemical Formula
- C24H21F2NO3
- CAS Number
- 163222-33-1
- Unique Ingredient Identifier
- EOR26LQQ24
- Background
Ezetimibe is a lipid-lowering compound that inhibits intestinal cholesterol and phytosterol absorption. The discovery and research of this drug began in the early 1990s, after the intravenous administration of radiolabelled ezetimibe in rats revealed that it was being localized within enterocytes of the intestinal villi - this prompted studies investigating ...
- Indication
Ezetimibe is indicated to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with primary hyperlipidemia, alone or in combination with an HMG-CoA reductase inhibitor (statin). It is also indicated to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with mixed hyperlipidemia in combination with fenofibrate, and to reduce elevated...
- Associated Conditions
- Elevated Blood Lipids, Elevated sitosterol and campesterol
- Associated Therapies
- -
Cholesterol-lowering Effects of nutraceuticaLs Versus Ezetimibe in Statin-intolerant Patients
- Conditions
- Interventions
- First Posted Date
- 2013-03-08
- Last Posted Date
- 2013-03-08
- Lead Sponsor
- University of Roma La Sapienza
- Target Recruit Count
- 200
- Registration Number
- NCT01807078
- Locations
- 🇮🇹
Sapienza University, Rome, Lazio, Italy
Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis
- First Posted Date
- 2013-01-11
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 50
- Registration Number
- NCT01766713
- Locations
- 🇺🇸
University of California, San Diego, San Diego, California, United States
LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2
- First Posted Date
- 2013-01-09
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 2067
- Registration Number
- NCT01763866
- Locations
- 🇬🇧
Research Site, Whitby, United Kingdom
Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2
- Conditions
- Interventions
- First Posted Date
- 2013-01-09
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 615
- Registration Number
- NCT01763827
- Locations
- 🇹🇷
Research Site, Istanbul, Turkey
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2
- Conditions
- Interventions
- First Posted Date
- 2013-01-09
- Last Posted Date
- 2020-07-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 307
- Registration Number
- NCT01763905
- Locations
- 🇬🇧
Research Site, West Bromwich, United Kingdom
Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)
- Conditions
- Interventions
- First Posted Date
- 2012-11-21
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 305
- Registration Number
- NCT01730053
- Locations
- 🇪🇸
(2 Locations), Barcelona, Spain
🇲🇽(3 Locations), Guadalajara, Mexico
Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)
- Conditions
- Interventions
- First Posted Date
- 2012-11-21
- Last Posted Date
- 2015-08-31
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 355
- Registration Number
- NCT01730040
Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2012-11-08
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 79
- Registration Number
- NCT01723735
- Locations
- 🇫🇷
Investigational Site Number 250001, Rennes, France
🇫🇷Investigational Site Number 250002, Rueil Malmaison, France
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
- Conditions
- Interventions
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2020-06-23
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 314
- Registration Number
- NCT01709513
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia
- Conditions
- Interventions
- First Posted Date
- 2012-07-19
- Last Posted Date
- 2015-11-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 103
- Registration Number
- NCT01644474
- Locations
- 🇺🇸
Investigational Site Number 840603, Overland Park, Kansas, United States
🇺🇸Investigational Site Number 840601, Cincinnati, Ohio, United States
🇳🇱Investigational Site Number 528602, Groningen, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.